All In Biotech

NDA 021806 · Teva Pharms

Vandazole

Metronidazole · Vaginal · Nitroimidazole Antimicrobial

Last checked: Nov 19, 2026Latest source record: Feb 11, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

May 20, 2005

Approved uses

1

Original approval plus efficacy supplements

Registered trials

728

132 Phase 3, 52 recruiting

FAERS reports

48,130

41,923 serious, 5,412 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 2, 2025.

VANDAZOLE ® is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis) in post-menarchal females. VANDAZOLE is a nitroimidazole antimicrobial indicated for the treatment of bacterial vaginosis in post-menarchal females. ( 1 )

Mechanism: Metronidazole is an antibacterial drug [see Clinical Pharmacology, Microbiology ( 12.4 )]

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 20, 2005 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
1 products under this application
  • VANDAZOLE · METRONIDAZOLE 0.75% · GEL, VAGINAL · Prescription · TE BX

Clinical trials

Interventional ClinicalTrials.gov studies with "Metronidazole" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,663
  • nausea3,461
  • off label use3,386
  • diarrhoea2,713
  • vomiting2,329
  • pyrexia2,288
  • headache2,259
  • pain2,123
  • abdominal pain2,122
  • fatigue1,960
  • dizziness1,686
  • condition aggravated1,637

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004459
2005480
2006483
2007512
2008320
2009677
2010859
20111,167
20121,431
20131,112
20141,452
20152,169
20162,477
20172,510
20184,185
20194,493
20203,820
20213,875
20223,401
20233,458
20243,163
20253,437
20262,187

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vandazole (Metronidazole)

2024 spending

$215K

Beneficiaries

2,418

3,115 claims

Per beneficiary

$89

$0.94 per unit

View as table
YearSpending
2020$869,884
2021$478,693
2022$335,481
2023$269,456
2024$215,227

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,032 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.